Monitoring and Safety of Azathioprine Therapy in Inflammatory Bowel Disease

키워드

참고문헌 (58)

1. Sandborn W, "Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease", Cochrane Database Syst Rev, 2 (2000)
2. Hibi T, "Novel pathophysiological concepts of inflammatory bowel disease", J Gastroenterol, 41, pp.10~16 (2006)
3. Hindorf U, "Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease", Gut, 55, pp.1423~1431 (2006)
4. Gearry RB, "Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease", Pharmacoepidemiol Drug Saf, 13, pp.563~567 (2004)
5. Goldenberg BA, "The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease", Am J Gastroenterol, 99, pp.1744~1748 (2004)
6. Cuffari C, "Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease", Gut, 48, pp.642~646 (2001)
7. Derijks LJ, "Review article: thiopurines in inflammatory bowel disease", Aliment Pharmacol Ther, 24, pp.715~729 (2006)
8. Zelinkova Z, "Inosine triphosphate pyrophosphatase and thiopurine s-methyltransferase genotypes relationship to azathioprine-induced myelosuppression", Clin Gastroenterol Hepatol, 4, pp.44~49 (2006)
9. Gearry RB, "Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease", J Gastroenterol Hepatol, 20, pp.1149~1157 (2005)
10. Sahasranaman S, "Clinical pharmacology and pharmacogenetics of thiopurines", Eur J Clin Pharmacol, 64, pp.753~767 (2008)
11. Sandborn WJ, "Rational dosing of azathioprine and 6-mercaptopurine", Gut, 48, pp.591~592 (2001)
12. Palmieri O, "Sequential evaluation of thiopurine methyltransferase, inosine triphosphate pyrophosphatase, and HPRT1 genes polymorphisms to explain thiopurines' toxicity and efficacy", Aliment Pharmacol Ther, 26, pp.737~745 (2007)
13. Dubinsky MC, "Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease", Gastroenterology, 118, pp.705~713 (2000)
14. Ooi CY, "Thiopurine metabolite monitoring in paediatric inflammatory bowel disease", Aliment Pharmacol Ther, 25, pp.941~947 (2007)
15. Wright S, "Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease", Gut, 53, pp.1123~1128 (2004)
16. Dubinsky MC, "Optimizing immunomodulator therapy for inflammatory bowel disease", Curr Gastroenterol Rep, 5, pp.506~511 (2003)
17. Dubinsky MC, "6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease", Gastroenterology, 122, pp.904~915 (2002)
18. Derijks LJ, "Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy", Ther Drug Monit, 26, pp.311~318 (2004)
19. Haines ML, "Clinical usefulness of therapeutic drugmonitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease", Inflamm Bowel Dis, 17, pp.1301~1307 (2011)
20. Lichtenstein GR, "Tremaine W; American Gastroenterological Association. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease", Gastroenterology, 130, pp.935~939 (2006)
21. Dignass A, "European Crohn's and Colitis Organisation (ECCO). The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: current management", J Crohns Colitis, 4, pp.28~62 (2010)
22. Andoh A, "Monitoring 6-thioguanine nucleotide concentrations in Japanese patients with inflammatory bowel disease", J Gastroenterol Hepatol, 23, pp.1373~1377 (2008)
23. Komiyama T, "Lower doses of 6-mercaptopurine", azathioprine bring enough clinical efficacy and therapeutic concentration of erythrocyte 6-mercaptopurine metabolite in Japanese IBD patients, 2008, pp.2, 315~321
24. Ohtsuka Y, "Monitoring 6-thioguanine nucleotide concentrations in Japanese children and adolescents with inflammatory bowel disease", J Gastroenterol Hepatol, 25, pp.1626~1630 (2010)
25. Schwab M, "Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism", Pharmacogenetics, 12, pp.429~436 (2002)
26. Lewis LD, "Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction", 62, pp.464~475 (1997)
27. Green JR, "Balsalazide and azathioprine or 6-mercaptopurine", Gastroenterology, 117, pp.1513~1514 (1999)
28. Kennedy DT, "Azathioprine and allopurinol: the price of an avoidable drug interaction", Ann Pharmacother, 30, pp.951~954 (1996)
29. Roblin X, "Drug interaction between infliximab and azathioprine in patients with Crohn's disease", Aliment Pharmacol Ther, 18, pp.917~925 (2003)
30. Schaeffeler E, "Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German- Caucasians and identification of novel TPMT variants", Pharmacogenetics, 14, pp.407~417 (2004)
31. Weinshilboum RM, "Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity", Am J Hum Genet, 32, pp.651~662 (1980)
32. Derijks LJ, "Pharmacogenetics of thiopurines in inflammatory bowel disease", Curr Pharm Des, 16, pp.145~154 (2010)
33. Hon YY, "Polymorphism of the thiopurine S-methyltransferase gene in African-Americans", Hum Mol Genet, 8, pp.371~376 (1999)
34. Otterness D, "Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms", Clin Pharmacol Ther, 62, pp.60~73 (1997)
35. Yates CR, "Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance", Ann Intern Med, 126, pp.608~614 (1997)
36. Cao Q, "Thiopurine methyltransferase gene polymorphisms in Chinese patients with inflammatory bowel disease", Digestion, 79, pp.58~63 (2009)
37. Zhu Q, "Thiopurine methyltransferase gene polymorphisms and activity in Chinese patients with inflammatory bowel disease treated with azathioprine", Chin Med J, 125, pp.3665~3670 (2012)
38. Hibi T, "Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis", J Gastroenterol, 38, pp.740~746 (2003)
39. Kim S, "Validation of new allele-specific real-time PCR system for thiopurine methyltransferase genotyping in Korean population", Biomed Res Int, 2013, pp.305704~ (2013)
40. Kim JH, "Influences of thiopurine methyltransferase genotype and activity on thiopurine-induced leukopenia in Korean patients with inflammatory bowel disease: a retrospective cohort study", J Clin Gastroenterol, 44, pp.e242~248 (2010)
41. Jung YS, "Correlation of genotypes for thiopurine methyltransferase and inosine triphosphate pyrophosphatase with long-term clinical outcomes in Korean patients with inflammatory bowel diseases during treatment with thiopurine drugs", J Hum Genet, 55, pp.121~123 (2010)
42. Lennard L, "Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations", Clin Pharmacol Ther, 41, pp.18~25 (1987)
43. Lennard L, "Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism", Clin Pharmacol Ther, 46, pp.149~154 (1989)
44. Cuffari C, "Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease", Clin Gastroenterol Hepatol, 2, pp.410~417 (2004)
45. Lennard L, "Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia", Lancet, 336, pp.225~229 (1990)
46. Hindorf U, "Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease", Aliment Pharmacol Ther, 24, pp.331~342 (2006)
47. Prefontaine E, "Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease", Cochrane Database Syst Rev, 4 (2009)
48. Fraser AG, "The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review", Gut, 50, pp.485~489 (2002)
49. Derijks LJ, "Pharmacokinetics of 6-thioguanine in patients with inflammatory bowel disease", Ther Drug Monit, 28, pp.45~50 (2006)
50. Haglund S, "IMPDH activity in thiopurine-treated patients with inflammatory bowel disease - relation to TPMT activity and metabolite concentrations", Br J Clin Pharmacol, 65, pp.69~77 (2008)
51. Gilissen LP, "Therapeutic drug monitoring in patients with inflammatory bowel disease and established azathioprine therapy", Clin Drug Investig, 24, pp.479~486 (2004)
52. Kandiel A, "Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine", Gut, 54, pp.1121~1125 (2005)
53. Kotlyar DS, "A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease", Clin Gastroenterol Hepatol, 9, pp.36~41 (2011)
54. Shale M, "Hepatosplenic T cell lymphoma in inflammatory bowel disease", Gut, 57, pp.1639~1641 (2008)
55. Belhadj K, "Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients", Blood, 102, pp.4261~4269 (2003)
56. Tey SK, "Post-transplant hepatosplenic T-cell lymphoma successfully treated with HyperCVAD regimen", Am J Hematol, 83, pp.330~333 (2008)
57. François A, "Hepatosplenic gamma", delta T-cell lymphoma: a report of two cases in immunocompromised patients, associated with isochromosome, 1997, pp.21, 781~790
58. Armstrong RG, "Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case-control study", Am J Gastroenterol, 105, pp.1604~1609 (2010)

관련 논문AI추천